CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 99 enrolled
Drug / intervention
Anakinra 100 mg +2 moredrug
Likely dose
Anakinra 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01950299
NCT01950299Phase 3Completed
CompareCT.gov

Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3

Virginia Commonwealth University·interventional·Posted Sep 25, 2013·Updated Dec 18, 2019

In Brief

A Phase 3 clinical trial evaluating Anakinra 100 mg and Placebo for Acute Myocardial Infarction. Completed, enrolled 99 participants across 2 sites.

Detailed Summary

VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 25, 2013
Enrollment StartJul 1, 2014
Primary CompletionDec 23, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 12.8 years ago

Interventions

Anakinra 100 mgdrug

Anakinra 100 mg starting immediately and then every 24 hours

Anakinra 100 mgdrug

Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)

Placebodrug

Placebo 0.67 ml injections twice daily